

VCN Biosciences exposes to European Medicines Agency and Spanish Medicines Authority its development for VCN-01

L'Hospitalet de Llobregat, May 2012. VCN Biosciences, a company specialized in the development of new biotechnological products for the treatment of cancer, completed last winter a round of consultation with the European Medicines Agency (EMA) and the Spanish Medicines Authorities (AEMPS) to discuss the proposed development for VCN-01, its most advanced candidate for treatment of pancreatic cancer. The company obtained a positive opinion from the Innovative Task Force Office (a multidisciplinary group within the EMA including scientific, regulatory and legal competences) and AEMPS (Oficina de Investigación Independiente) for its preclinical program, which is expected to be finished in the next months. VCN plans to apply for authorization of its clinical program with VCN-01 by intravenous and intratumoral administration during the first half of next year.



